Lexeo Therapeutics (LXEO) Cash & Equivalents (2022 - 2026)

Lexeo Therapeutics has disclosed Cash & Equivalents across 5 years of filings, most recently posting $71.8 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $71.8 million, up 148.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $71.8 million (up 148.22% YoY), and the FY2025 annual result was $63.0 million, up 79.93% from the prior year.
• Cash & Equivalents came in at $71.8 million for Q1 2026 at Lexeo Therapeutics, up from $63.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $195.1 million in Q1 2024 to a low of $28.9 million in Q1 2025.
• The 5-year median for Cash & Equivalents is $71.8 million (2026), against an average of $87.0 million.
• Across the five-year window, Cash & Equivalents surged 342.89% in 2024 and plunged 85.18% in 2025, its largest moves.
• Lexeo Therapeutics' Cash & Equivalents stood at $77.3 million in 2022, then soared by 57.06% to $121.5 million in 2023, then slumped by 71.17% to $35.0 million in 2024, then jumped by 79.93% to $63.0 million in 2025, then advanced by 13.92% to $71.8 million in 2026.
• The last three Cash & Equivalents figures came in at $71.8 million (Q1 2026), $63.0 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.